Session Type
Date Time

Prevention methods and practices are essential tools in the effort to end the HIV epidemic, and tremendous strides have been made in the last decade. What's the next phase of HIV prevention research and how do we work together to achieve the vision of preventing new HIV transmissions by using proven interventions? Please join global community leaders and Gilead clinical leadership for an in-depth scientific exchange on the rapidly changing landscape of HIV prevention, including the role of community collaboration, new mechanisms of action, and long-acting therapies that represent potential future innovative solutions and substantial advances in the field.

SA04.01 Welcome and Introduction
Moupali DAS, Gilead Sciences, United States
Jared BAETEN, Gilead Sciences, United States
Linda-Gail BEKKER, Desmond Tutu Healthcare Foundation, South Africa
SA04.02 A Conversation with Global Clinical, Community, and Stakeholder Leaders: How to Best Advance Novel HIV Prevention Strategies Together
Quarraisha ABDOOL KARIM, Center for the AIDS Programme of Research in South Africa (CAPRISA), South Africa
Flavia MATOVU KIWEEWA, Makere University-Johns Hopkins University (MU-JHU), Uganda
Yvette RAPHAEL, Advocacy for Prevention of HIV and AIDS (APHA), South Africa
Ntando YOLA, University of Cape Town, South Africa
Hua WANG, Vaccine Research Center, NIAID, NIH, United States
Tiwonge KANYENDA, Clinton Health Access Initiative, United States